Researchers at the University of Alabama in Birmingham have made a significant breakthrough in the treatment of dyskinesia, a common side effect of long-term Parkinson’s disease treatment. By targeting the protein Activin A and treating dyskinesia as a “bad motor memory,” they were able to stop the development of uncontrollable movements in mouse models. This discovery has the potential to improve the quality of life for Parkinson’s patients by extending the effectiveness of current treatments.
Parkinson’s disease is a neurodegenerative disorder caused by the death of dopamine-producing neurons. To address dopamine deficiency, clinicians prescribe L-DOPA, which can lead to dyskinesia in some patients over time. Dyskinesia is characterized by involuntary movements and postures, making daily tasks challenging for patients. However, researchers found that by inhibiting Activin A, they could prevent dyskinesia from developing in the first place, allowing patients to continue their treatment for a longer duration.
The study, published in The Journal of Neuroscience, highlighted the importance of understanding dyskinesia as a form of bad motor memory. By examining changes in gene expression in the striatum, researchers identified D1-MSNs as the cells storing the bad motor memory. These neurons behaved similarly to those in the hippocampus when forming a memory and expressed genes indicating L-DOPA activation and the creation of new connections. Inhibiting Activin A successfully prevented dyskinesia symptoms in mouse models, erasing the brain’s memory of the motor response to L-DOPA.
Karen Jaunarajs, PhD, assistant professor at UAB, explained that the study aimed to establish a comprehensive gene expression profile across different cell types in the striatum during dyskinesia development. By identifying Activin A as a key protein involved in dyskinesia, researchers hope to target this pathway to prolong the effectiveness of L-DOPA for Parkinson’s patients. Dr. Chandril Chugh, a neurologist not involved in the study, noted the importance of this research in enhancing our understanding of dyskinesias post-treatment and improving patient care and satisfaction.
Overall, this research has significant implications for the Parkinson’s disease community. By targeting Activin A and treating dyskinesia as a bad motor memory, researchers have found a potential way to prevent this debilitating side effect of long-term L-DOPA treatment. The hope is that these findings will pave the way for new therapeutic targets and ultimately improve the lives of Parkinson’s patients.
